Drugs / NORS
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04337918 | May 2020 → Jan 2021 | COVID-19 | Sanotize Research and Development corp. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NORS | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04337918 ↗ |
| Known as | Nitric Oxide Releasing Solution | “NORS (Nitric Oxide Releasing Solution)” NCT04337918 ↗ |
| Modality | Other / unclassified | “using a formulation called Nitric Oxide Releasing Solution (NORS)” NCT04337918 ↗ |
| Route | Other | “NORS treatment will consist of daily self-administration of three routes; Nitric Oxide Gargle (NOG) every morning, Nitric Oxide Nasophyaryngeal Irrigation (NONI) every evening,...” NCT04337918 ↗ |